<DOC>
	<DOCNO>NCT02682927</DOCNO>
	<brief_summary>This multicenter , double-blind , parallel-group , placebo-controlled , study assess efficacy , safety , PK ZX008 use adjunctive therapy uncontrolled seizure pediatric young adult subject Dravet syndrome . After initial Screening Baseline chart seizure frequency , subject qualify study randomize ( 1:1:1 ) receive either ZX008 ( 0.2 mg/kg/day , 0.8 mg/kg/day ; maximum dose : 30 mg/day ) placebo . Randomization stratify age group ( &lt; 6 year , â‰¥6 18 year ) . All subject titrate randomize dose 14-day Titration Period . Following titration , subject continue treatment randomly assign dose 12-week Maintenance Period . Subjects exit study undergo 2-week taper , unless enroll follow-on study . Subjects follow post-study safety monitoring . Parents/caregivers use diary daily record number/type seizure , dose , use rescue medication .</brief_summary>
	<brief_title>A Trial Two Fixed Doses ZX008 ( Fenfluramine HCl ) Children Young Adults With Dravet Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>Key Male nonpregnant , nonlactating female , age 2 18 year , inclusive day Screening Visit . Clinical diagnosis Dravet syndrome , convulsive seizure completely control current antiepileptic drug . Must minimum # convulsive seizure per 4week period past 12 week prior screen All medication intervention epilepsy must stable least 4 week prior screen expect remain stable throughout study . No cardiovascular cardiopulmonary abnormality base ECHO , ECG physical examination Parent/caregiver willing able compliant diary completion , visit schedule study drug accountability . Key Pulmonary arterial hypertension . Current past history cardiovascular cerebrovascular disease , cardiac valvulopathy , myocardial infarction stroke . Current past history glaucoma . Moderate severe hepatic impairment . Receiving concomitant therapy : anorectic agent ; monoamineoxidase inhibitor ; medication act via serotonin include serotonin reuptake inhibitor ; atomoxetine , centrallyacting noradrenergic agonist ; cyproheptadine . Currently receive receive stiripentol past 21 day prior Screening . Currently take carbamazepine , oxcarbamazepine , eslicarbazepine , phenobarbital , phenytoin , take within past 30 day . Positive result tetrahydrocannabinol ( THC ) cannabidiol ( CBD ) test Screening Visit . A clinically significant medical condition , would interfere study participation , collection study data , pose risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>seizure</keyword>
	<keyword>tonic-atonic</keyword>
	<keyword>clonic</keyword>
	<keyword>epilepsy</keyword>
	<keyword>myoclonic</keyword>
	<keyword>encephalopathy</keyword>
</DOC>